A Novel Aptamer LL4A Specifically Targets Vemurafenib-Resistant Melanoma through Binding to the CD63 Protein

• Main Authors: Hui Li (Author), Juan Liu (Author), Xiaojuan Xiao (Author), Shuming Sun (Author), Hui Zhang (Author), Yibin Zhang (Author), Weihua Zhou (Author), Bin Zhang (Author), Mridul Roy (Author), Hong Liu (Author), Mao Ye (Author), Zi Wang (Author), Feng Liu-Smith (Author), Jing Liu (Author)
• Format: Book
• Published: Elsevier, 2019-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Melanoma is a highly aggressive tumor with a poor prognosis, and half of all melanoma patients harbor BRAF mutations. A BRAF inhibitor, vemurafenib (PLX4032), has been approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to treat advanced melanoma patients with B...